Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Abstract

BackgroundProteomic studies of respiratory disorders have the potential to identify protein biomarkers for diagnosis and disease monitoring. Utilisation of sensitive quantitative proteomic methods creates opportunities to determine individual patient proteomes. The aim of the current study was to determine if quantitative proteomics of bronchial biopsies from asthmatics can distinguish relevant biological functions and whether inhaled glucocorticoid treatment affects these functions.MethodsEndobronchial biopsies were taken from untreated asthmatic patients (n = 12) and healthy controls (n = 3). Asthmatic patients were randomised to double blind treatment with either placebo or budesonide (800 μg daily for 3 months) and new biopsies were obtained. Proteins extracted from the biopsies were digested and analysed using isobaric tags for relative and absolute quantitation combined with a nanoLC-LTQ Orbitrap mass spectrometer. Spectra obtained were used to identify and quantify proteins. Pathways analysis was performed using Ingenuity Pathway Analysis to identify significant biological pathways in asthma and determine how the expression of these pathways was changed by treatment.ResultsMore than 1800 proteins were identified and quantified in the bronchial biopsies of subjects. The pathway analysis revealed acute phase response signalling, cell-to-cell signalling and tissue development associations with proteins expressed in asthmatics compared to controls. The functions and pathways associated with placebo and budesonide treatment showed distinct differences, including the decreased association with acute phase proteins as a result of budesonide treatment compared to placebo.ConclusionsProteomic analysis of bronchial biopsy material can be used to identify and quantify proteins using highly sensitive technologies, without the need for pooling of samples from several patients. Distinct pathophysiological features of asthma can be identified using this approach and the expression of these features is changed by inhaled glucocorticoid treatment. Quantitative proteomics may be applied to identify mechanisms of disease that may assist in the accurate and timely diagnosis of asthma.Trial registrationClinicalTrials.gov registration NCT01378039

Strategies for Molecular Classification of Asthma Using Bipartite Network Analysis of Cytokine Expression

“…Though asthma classification was not attempted, important associations between subgroups of protein classes like Toll-like receptors and chemokines were demonstrated. Recently, networks have also been used to determine if quantitative proteomics of bronchial biopsies from asthmatics can distinguish biological functions [32]. Though networks analyses are finding increasing use in the published literature to analyze a wide range of scientific data such as social networks, occurrence of comorbidities and gene–gene interactions [33•], these unipartite analyses show only one part of a bipartite (eg, subject–cytokine) relationship.…”

Proteomics: Clinical and research applications in respiratory diseases

“…These authors used pathway analysis to identify biologically important functional pathways including acute phase response, cell-cell signalling and tissue development in asthmatic airways compared with controls. 69 Hamsten et al also demonstrated alterations in CCL5 plasma protein levels with significantly lower levels reported in children with persistent asthma compared with controls. 70 Wu et al used LC-MS/MS of BALF samples after allergen challenge in asthma patients to describe the complex biological pathways activated in the lung.…”

“…A further study of endobronchial biopsies in a small number of asthma patients and healthy volunteers using MS also identified CCL5 as a biomarker. These authors used pathway analysis to identify biologically important functional pathways including acute phase response, cell–cell signalling and tissue development in asthmatic airways compared with controls . Hamsten et al .…”

Asthma phenotyping, therapy, and prevention: what can we learn from systems biology?

“…It is possible to use omics data analysis to assess the global effect of anti-asthma drug administration. O'Neil and collaborators used quantitative proteomics on asthmatic bronchi to investigate the effects of inhaled glucocorticoid treatment (72). The authors carried out a double-blind treatment experiment with either placebo or budesonide (800 μg daily for 3 mo) on a cohort of 15 subjects, of which 12 were patients with asthma.…”